UNSPSC 51282812: Metronidazole phosphate

This classification denotes an antiprotozoal agent and antimicrobial with the molecular formula C6H10N3O6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L500PR95QA, chemically known as 1h-imidazole-1-ethanol, 2-methyl-5-nitro-, dihydrogen phosphate (ester) but more generally known as metronidazole phosphate, which bears US NIH Compound Identifier 51794. Most nations, for tariff and trade purposes, schedule metronidazole phosphate under HS 29332990 and SITC 51573.

As of Q4 2014, METRONIDAZOLE PHOSPHATE remains US FDA's Preferred Term for this commodity. Metronidazole phosphate bears US NLM identifiers UMLS ID C0887130 and NCI Concept Code C90619. SMILES: CC1NCC(N1CCOP(=O)(O)O)[N+](=O)[O-].

UNSPSC 51282812 Metronidazole phosphate is a Commodity code that nominally designates a single antiprotozoal and anaerobic-bacterial pharmaceutical agent, yet the recent state and local solicitations tagged under this code show little alignment with the product itself. The recent opportunities span pharmaceuticals procurement more broadly — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals through cooperative purchasing — but do not center on metronidazole phosphate as a procurement focus. This code appears to see minimal targeted activity for the specific drug named; the tagging mismatch suggests either broad pharmaceutical-category consolidation in the posting system or administrative miscoding in the source records.

The issuing bodies span state health and human services commissions (Texas HHS, Minnesota Department of Administration), county health departments (Seminole County, Florida), and municipal fire and rescue services (City of Tampa). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) cooperative vehicle shows state and local jurisdictions pooling demand through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson). Geographic activity centers on Florida, Texas, and Minnesota, with the MMCAP contract extending to Oregon participants. Recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems with a July 26, 2023 response date; the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division due March 13, 2026 (estimated contract value $700,000), sheltered to certified Small Local Business Enterprises with a 5% bid discount capped at $10,000; Texas HHS's RFI on direct-to-manufacturer prescriptions due April 3, 2026; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, specifying distribution through three authorized wholesalers and performance penalties of $200 to $1,500 per violation.